June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 24, 2025

Best Fluid for Sepsis? Crystalloids Lead

A network meta-analysis of 32 randomized trials found that balanced crystalloid solutions were associated with lower mortality, reduced acute kidney injury, and shorter hospital stays in patients with sepsis or septic shock.

Conexiant

June 24, 2025

FDA Approves At-Home Lupus Nephritis Therapy

The FDA has approved a subcutaneous autoinjector of belimumab for at-home treatment of pediatric lupus nephritis.

Conexiant

June 18, 2025

SGLT2 Inhibitor Empagliflozin Preserves Kidney Function After Heart Attack

A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.

Conexiant

June 10, 2025

Does Combination Therapy Improve Albuminuria?

Finerenone plus empagliflozin reduced urinary albumin-to-creatinine ratio by 29% to 32% more than either drug alone in patients with chronic kidney disease and type 2 diabetes.

Conexiant

June 09, 2025

NIH Staff Challenge Leadership's Research Policies

Federal scientists release formal dissent declaration opposing administration's grant terminations and policy changes affecting biomedical research.

Conexiant

June 02, 2025

New COVID Vaccine Approved for High-Risk Groups

After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant